Boston Scientific Corporation
Contrarian
Health Care
Large cap
7/6/26 (1mo ago)
closed Aug 11, 2026
Entry$44.60Close$50.99PnL+14.33%
Angle A full round trip to 2022 support leaves BSX priced far below sell-side targets as buyback support absorbs the flush.
BSX has been punished like a broken compounder despite an active buyback, with the accelerated repurchase at $52.68 now far above spot and highlighting the severity of the capitulation [
#2]. The reversal case is sentiment and positioning: shares have round-tripped to 2022 levels near a historic support trendline, while referenced upside to average analyst targets remains unusually wide [
#4,
#5].
Catalyst Second-half mean reversion as support holds and investors revisit the analyst-target gap after the forced selling phase.
AI Status: BSX closed with a +14.33% realized gain after a 26-day rebound from 2022 support, finishing just 0.45% below peak.
Contrarian
Finance
Mid cap
7/2/26 (1mo ago)
closed Aug 6, 2026
Entry$2.17Close$1.18PnL-45.73%
Angle KBW's Outperform upgrade gives UWMC a fresh risk-reward reset after rate, leverage, and dividend fears washed out the stock.
UWMC's bounce has a tweet-backed sentiment hook: Keefe Bruyette upgraded UWM to Outperform while setting a $3.75 target, materially above the $2.22 close [
#1,
#15]. The setup is contrarian because BTIG's cited pushback says the stock remains weak on rate, leverage, and dividend concerns, so the upgrade suggests the bearish narrative may be over-discounted as daily momentum turns [
#8].
Catalyst The re-rating window is the next 1-6 weeks as investors digest KBW's upgrade against a crowded negative mortgage-lender narrative.
AI Status: UWMC closed at a 45.73% loss after the KBW upgrade bounce failed and the stock kept grinding lower in a entrenched downtrend.